New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Siefker-Radtke talks to ecancertv at ASCO GU 2015 about the results of a phase II clinical trial of DDMVAC plus bevacizumab and the merits of using basal subtyping to individualise treatment approaches.
New classification for identifying HR myeloma based on cytogenetic abnormalities
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Looking at real world evidence on PSA testing in prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
Overview of the management of HER2-low breast cancer patients